Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The claim that severe acute exacerbation of hepatitis B can occur after stopping BIKTARVY is directly supported by the provided FDA label excerpts (Sections 5.1 and 17) with no contradictions.
Category Scores
Accurate Statements
Post-treatment acute exacerbation of hepatitis B can occur after stopping BIKTARVY.
Section 5.1: Severe acute exacerbations of hepatitis B have been reported in patients with HIV-1 and HBV who have discontinued products containing FTC and/or TDF and may occur with discontinuation of BIKTARVY. Section 17 reiterates that severe acute exacerbations may likewise occur with discontinuation of BIKTARVY.
Unsupported Statements
Contradictions
Important Omissions
No inclusion of the label’s recommended actions (close clinical and laboratory monitoring for at least several months after stopping, and consideration of anti-hepatitis B therapy).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claim is an on-label warning statement about risk after discontinuation; however, it does not specify the label’s monitoring and potential anti-HBV therapy guidance.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The response states the risk but omits the label’s recommended monitoring duration and consideration of anti-HBV therapy.
Suggested Improvement
Add that patients who discontinue BIKTARVY should be closely monitored with clinical and laboratory follow-up for at least several months after stopping, and that anti-hepatitis B therapy may be warranted.